News & Events

October 22, 2026

Apollo Therapeutics Announces Science Translational Medicine Publication Supporting APL-9796 as a Potential Disease-Modifying Approach for Pulmonary Hypertension

August 25, 2026

Apollo Therapeutics Announces Positive Immunogenicity Data and Cross-Species Activity from Phase 1 Trial of APL-10456, a Pan-Rhinovirus Vaccine for the Prevention of COPD Exacerbations

June 09, 2026

Apollo Therapeutics Appoints Timothy P. Walbert as Chairman of the Board

September 16, 2025

Apollo Therapeutics’ Anti-IL-18 Antibody Camoteskimab Met the Primary Endpoint in a Double-Blind, Randomized, Placebo-Controlled Phase 2a Clinical Trial in Atopic Dermatitis

May 05, 2025

Apollo Therapeutics marks World Pulmonary Hypertension Day with update on the clinical development of APL-9796 (anti-ZIP12 mAb) for the treatment of Pulmonary Hypertension

January 08, 2025

Apollo appoints new Special Advisor, Dr Husseini Manji

November 12, 2024

Apollo Therapeutics Signs Exclusive Ex-China License From Sunshine Lake Pharma for Clinical-Stage FGF21 / GLP-1 Dual Receptor Agonist, a Therapeutic With Major Commercial Potential in Multiple Indications

October 16, 2024

Apollo appoint Dr Dipender Gill to the strategic advisory board

July 22, 2024

Apollo Therapeutics and the University of Oxford enter into drug discovery and development collaboration

Apollo Therapeutics will inject capital and expertise into pipeline of potentially lifesaving medici